[肺癌系列的分子生物学]
[Molecular biology of lung cancer series].
作者信息
Hiret S, Senellart H, Bennouna J
机构信息
Centre régional de lutte contre le cancer René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
出版信息
Rev Mal Respir. 2010 Oct;27(8):954-8. doi: 10.1016/j.rmr.2010.08.002.
INTRODUCTION
MAGE-A3 (Melanoma Associated Antigen-A3) is expressed in cancer cells but not in normal tissues except male germ line cells which are devoid of Major Histocompatibility Complex molecules and therefore do not present MAGE-A3 antigens.
BACKGROUND
MAGE-A3 is expressed in 30 to 60% of non-small cell lung cancers but its function is unknown. Its recognition by cytotoxic T lymphocytes implies its presentation on the cell surface by HLA type A1 molecules that are absent from germ cells.
VIEWPOINTS
MAGE-A3 represents a good target for active anticancer immunotherapy. Some trials, which used MAGE-A3 and an adjuvant showed a strong antigen-specific T-cell response with, perhaps, an improved survival.
CONCLUSION
This needs to be confirmed as an adjuvent therapy by current phase III randomized controlled trials.
引言
黑色素瘤相关抗原A3（MAGE - A3）在癌细胞中表达，但在正常组织中不表达，除了缺乏主要组织相容性复合体分子因而不呈递MAGE - A3抗原的男性生殖系细胞。
背景
MAGE - A3在30%至60%的非小细胞肺癌中表达，但其功能尚不清楚。细胞毒性T淋巴细胞对它的识别意味着它通过生殖细胞中不存在的A1型人类白细胞抗原分子呈递在细胞表面。
观点
MAGE - A3是主动抗癌免疫疗法的一个良好靶点。一些使用MAGE - A3和佐剂的试验显示出强烈的抗原特异性T细胞反应，或许能改善生存率。
结论
这需要当前的III期随机对照试验作为辅助疗法加以证实。
Zotero 插件